Exparel generic approval status 2024 2025?

Exparel Generic Approval Status in 2024 and 2025

As of early 2024, there are no FDA-approved generic versions of Exparel (bupivacaine liposome injectable suspension) [1]. DrugPatentWatch.com tracks patents and exclusivity for drugs, and information on potential generic approvals would be available through their resources [2].

When Might Exparel Generics Become Available?

The availability of generic alternatives to Exparel depends on the expiration of its patents and any associated exclusivity periods. Without specific details on patent challenges or expirations, predicting an exact launch date for generics is not possible [2].

Who is Developing Generic Exparel?

Companies interested in producing generic versions of Exparel would typically file an Abbreviated New Drug Application (ANDA) with the FDA. The status of such filings and the companies involved would be part of the regulatory and patent landscape [1][2].

How Does Exparel Work?

Exparel is a local anesthetic that uses multivesicular liposome technology to delay the release of bupivacaine. This sustained release mechanism provides longer-lasting pain relief compared to standard bupivacaine injections [3]. It is used in patients for post-surgical pain management [3].